Keystone Symposia

Whistler Conference Centre Floorplan

Registered Attendees

Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2004

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

HIV Vaccine Development: Progress and Prospects (X8)

Organizer(s) Norman L. Letvin, Nina Bhardwaj and Barney S. Graham
April 12—18, 2004
Whistler Conference Centre • Whistler, BC Canada
Abstract Deadline: Dec 11, 2003
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Feb 12, 2004

Sponsored by Wyeth Vaccines Research

Summary of Meeting:
The magnitude of the world-wide public health problem posed by HIV is well known. Control of the AIDS epidemic will only come with the development of a successful vaccine. The potential efficacy of both cellular and humoral immune responses in controlling HIV replication is now well documented. However, the ability of the virus to mutate away from recognition by T lymphocytes and neutralizing antibody continues to frustrate attempts to make a successful vaccine. A number of recent observations have dramatically increased the optimism of those involved in HIV vaccine development. It is now clear that vaccine-elicited cellular immune responses can contribute to containing the level of viral replication and delay the progression of clinical disease following an AIDS virus infection in nonhuman primates. It has also recently been shown that monoclonal antibodies that neutralize a diversity of HIV isolates can protect against HIV infection of nonhuman primates when passively administered to animals prior to challenge. Finally, a number of novel vaccine strategies are showing promise in early clinical trials in eliciting relevant immune responses in human volunteers. A meeting on HIV vaccines in 2004 will be extremely timely, in that data from large scale human trials of promising vaccine candidates will be available at that time for presentation. A number of early phase trials with a newer generation of vaccine candidates will also just be initiated and data will be available from those trials. Finally, new data from basic immunology and AIDS immunopathogenesis studies will be available for presentations that bear on the creation of new strategies for HIV vaccination. The Keystone HIV Vaccine Meeting has become recognized as the most important forum for presenting new data in this important area of research. The meeting is attended annually by the most important investigators in the field worldwide. There is every reason to suppose that this will continue to be the case.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time



Grand Foyer

Grand Foyer

Ballroom B, C
Keynote Session (Joint)

Ballroom B, C
* Norman L. Letvin, Beth Israel Deaconess Medical Center, USA

Gary J. Nabel, Sanofi, USA
The Gene Product Murr1 Restricts HIV-1 Replication in Resting CD4+ Lymphocytes

Wesley I. Sundquist, University of Utah School of Medicine, USA
The Biochemistry of HIV-1 Release



Lower Level
HIV Entry Mechanisms and Neutralizing Antibodies (Joint)

Ballroom B, C
* Joseph G. Sodroski, Dana-Farber Cancer Institute, USA
Innate Intracellular Immunity to HIV-1 in Old World Monkeys

David C. Montefiori, Duke University Medical Center, USA
Neutralizing Antibodies Induced by Candidate HIV-1 Vaccines

Alexandra Trkola, University of Zürich, Switzerland
Antibodies: Surrogate or Supporter of Protective Immunity?

Susan Zolla-Pazner, Icahn School of Medicine at Mount Sinai, USA
The V3 Loop: Always Changing, Always the Same

Gregory B. Melikian, Emory University, USA
Short Talk: Dissecting the Steps of HIV ENV-Induced Fusion: Coreceptor Engagement, Fusion Pore Formation, and Pore Enlargement

James Mark Binley, San Diego Biomedical Research Institute, USA
Short Talk: Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-HIV Monoclonal Antibodies and a Clade B HIV+ Plasma

Coffee Break

Grand Foyer
Poster Setup

Ballroom A, Grand Foyer
Poster Viewing

Ballroom A, Grand Foyer
Workshop 1: HIV Envelope Structure and Neutralization

Ballroom B, C
* Richard T. Wyatt, IAVI Neutralizing Antibody Center, The Scripps Research Institute, USA

Barna Dey, NIAID, National Institutes of Health, USA
Characterization of Mutant HIV-1 Envelope Glycoproteins Stabilized in the CD4-Bound Conformation

Kathy P. Fernando, University of Pennsylvania, USA
HIV Env Lacking CD4 Binding as a Vaccine Approach

Marie Pancera, Fred Hutchinson Cancer Research Center, USA
Characterization of Stabilized Trimeric HIV-1 gp120 Envelope Glycoprotein

Suganya Selvarajah, The Scripps Research Institute, USA
Modified gp140 Trimers to Elicit b12-Like Antibodies

Chinglai Yang, Emory University, USA
Characterization of an HA/Gp41 Chimeric Protein: Enhanced Interaction with the Broadly Neutralizing Monoclonal Antibody 2F5 against HIV

Jason E. Hammonds, Emory University, USA
Induction of Antibody Responses to CD4-Induced Epitopes by Induced Pseudovirions and Recombinant Protein Immunogens

Jonathan M. Gershoni, Tel Aviv University, Israel
Backtracking from mAb to Epitope - A Combinatorial Approach

Carolina Herrera, Imperial College, UK
Consequences of HIV-1 Env Cleavage on Antigenicity, Infectivity, and Neutralization

Gerald V. Quinnan, Jr., Uniformed Services University Health Sciences, USA
Protection Against Rhesus Monkey Adapted-SHIV Challenge by Active Induction of HIV-1 Neutralizing Antibodies or SIV gag-Specific Cytotoxic T Cells

Workshop 1: HIV Accessory Protein and Assembly
Attendance Limited to 125

Garibaldi A/B
* Wesley I. Sundquist, University of Utah School of Medicine, USA
Following the RNA

Melanie M. Ott, Gladstone Institutes, USA
SIRT1 Deacetylates the HIV Tat Protein and is Required for Tat-Mediated Transactivation of the HIV Promoter

Roger J. Pomerantz, Seres Therapeutics, Inc., USA
A Dead Box Protein is as a Critical Cellular Co-Factor of HIV-1 REV: Effects on Viral Persistence and Reservoirs in Different Cell-Types

Chad M. Swanson, King's College London, UK
A Link between Viral Assembly and Nuclear Export

Andrew J. Mouland, McGill University, Lady Davis Institute, Canada
The Specific Association of hnRNP A2 to its Cognate Response Sequence in HIV-1 RNA Implications in Viral Assembly

Heinrich Göttlinger, Dana Farber Cancer Institute, USA
Roles of AIP1 and ESCRT-III in HIV Budding

Marc C. Johnson, Cornell University, USA
Visual Comparison of Retroviral Late-Domain Phenotypes

Rebecca J. Loomis, University of North Carolina at Chapel Hill, USA
Citron Kinase, a RhoA Effector, Enhances HIV-1 Virion Release

Vicente Planelles, University of Utah, USA
The Mechanisms of HIV-1 VPR-Mediated G2 Arrest and Apoptosis: Role of the Host Cell DNA Damage Signaling Pathway

Coffee & Snacks Available

Grand Foyer
Natural SIV Infection: Lessons from the Monkey (Joint)

Ballroom B, C
* Paul M. Sharp, University of Edinburgh, UK
Evolution from SIV to HIV

Beatrice H. Hahn, University of Pennsylvania, USA
Molecular Epidemiology of Simian Immunodeficiency Virus Infection in Wild Chimpanzees

Mark B. Feinberg, IAVI International AIDS Vaccine Initiative, USA
Host-Virus Relationships Underlying Non-Pathogenic SIV Infections

Greg J. Towers, University College London, UK
Restriction of retroviral infection by TRIM5

Nathaniel R. Landau, New York University School of Medicine, USA
Short Talk: Mechanism of APOBEC3G Deamination of HIV Reverse Transcripts

Social Hour

Ballroom A, Grand Foyer
Poster Session 1

Ballroom A, Grand Foyer



Lower Level
Current Issues in the Clinical Evaluation of Vaccines

Ballroom B
John W. Shiver, Sanofi Pasteur, USA
Development of an HIV-1 Vaccine Based on Replication-Defective Adenovirus

* Barney S. Graham, NIAID, National Institutes of Health, USA
Update of Trials of Multi-Clade DNA and Recombinant Adenovirus Vaccines

Lawrence Corey, Fred Hutchinson Cancer Research Center, USA
Update of HVTN Clinical Trials

HIV Genome RNA: From the Nucleus to the Plasma Membrane

Ballroom C
* Tristram G. Parslow, Emory University, USA
The HIV-1 Genomic Dimer Interface as a Target for Structure-Based Drug Design

Kathleen A. Boris-Lawrie, Ohio State University, USA
The Destiny of Retroviral Unspliced RNA: Ribosome or Virion?

Casey D. Morrow, University of Alabama at Birmingham, USA
Selection of the tRNA Primer required for HIV Replication

Chantal Ehresmann, IBMC du Centre National de la Recherche Scientifique, France
The 5' -Untranslated Region of HIV-1 Genomic RNA: Structure and Functional Implications

James R. Williamson, The Scripps Research Institute, USA
Toward Inhibition of HIV Rev-RRE Interactions: Challenges for Targeting RNA

Coffee Break

Grand Foyer
Roundtable Discussion: Immunogenicity Criteria for Advancing Candidate Vaccines into Phase III Trials

Ballroom B
* Gary J. Nabel, Sanofi, USA

Dennis R. Burton, The Scripps Research Institute, USA
Criteria for Neutralizing Antibody Responses

Hana Golding, US Food and Drug Administration, USA
Regulatory Perspective

Emilio A. Emini, Bill and Melinda Gates Foundation, USA
Manufacturer's Perspective

John G. McNeil, Sanofi-Pasteur, USA
Clinical Perspective

Steve G. Self, Fred Hutchinson Cancer Research Center, USA
Statistical Perspective

Andrew J. McMichael, Oxford University, UK
Criteria for T Cell Responses

John P. Moore, Weill Medical College of Cornell University, USA
Criteria for Neutralizing Antibody Responses

Poster Setup

Ballroom A, Grand Foyer
Poster Viewing

Ballroom A, Grand Foyer
Workshop 2: Immunobiology of HIV Infection

Ballroom B
* Luis J. Montaner, Wistar Institute, USA

David Favre, GlaxoSmithKline, USA
Generation of Dysfunctional CD8+ T Cells in the Setting of HIV Infection

Daniel E. Kaufmann, University of Montreal, Canada
Promiscuous Presentation of the Same Epitopes by Different HLA Class II Alleles and Clustering of Overlapping Epitopes both Contribute to the High Frequency of Recognition by CD4 Cells of a Limited Subset of Gag and Nef HIV-1 Peptides

Christian Brander, Institut de Recerca de la Sida, IrsiCaixa, Spain
HLA-B63 (B*1516/B*1517) Presents HLA-B57 Restricted CTL Epitopes and is Associated with Slow HIV Disease Progression

Marie-Claire E. Gauduin, Texas Biomedical Research Institute, USA
Depletion of CD8+ Lymphocytes Results in Rebound Viremia in SIV-Infected Macaques with Undetectable Viral Replication following Early Antiretroviral Therapy

David A. Garber, Emory University, USA
Enhancing the Immunogenicity of MVA-based AIDS Vaccines

Shan Lu, University of Massachusetts Medical Center, USA
Immunogenicity of Monovalent and Polyvalent DNA Prime/Protein Boost Formulations Encoding Primary HIV-1 Env Antigens as Tested in Rabbits and Non-Human Primate Models

Workshop 2: The Viral Synapse

Ballroom C
* Michael H. Malim, King's College London, UK

Vincent Piguet, Cardiff University, UK
DC-SIGN-Mediated Infectious Synapse Formation Enhances Transfer of HIV Infection from Dendritic Cells to T Cells

Clare Jolly, University College London, UK
HIV-1 Exploits an Env-Induced Synapse in CD4+ T Cells

Philippe Gallay, The Scripps Research Institute, USA
A Highly Conserved Arginine in the V3 Loop of Gp120 Governs HIV-1 Binding to Coreceptors and Syndecans

Teunis B.H. Geijtenbeek, University of Amsterdam, Netherlands
Mechanisms of DC-Sign Mediated Function in HIV-1 Infection

Rahm Gummuluru, Boston University School of Medicine, USA
Mechanism of DC-SIGN Mediated HIV-1 Transmission

David McDonald, National Institute of Allergy and Infectious Disease, USA
Enhancement of HIV Infection by Activated Dendritic Cells Occurs via Trafficking through a CD81 Enriched Compartment

Ann-Marie M. Roy, University of California, San Francisco, USA
Impact of Coreceptor Use on HIV-1 Viral Output per Infected Cell

John Wilkinson, Westmead Millennium Institute, Australia
Increased HIV-1 Uptake in Immature Dendritic Cells and Increased Viral Transfer to CD4+ T Cells as a Result of Inhibition of the Endosomal - Lysosomal Degradation Pathway

Coffee & Snacks Available

Grand Foyer
Advances in Immunobiology

Ballroom B
Arlene H. Sharpe, Harvard Medical School, USA
Current Understanding of Immune Co-Stimulation

* Antonio Lanzavecchia, Vir Biotechnology, Inc., USA
Induction and Maintenance of Serological Memory

Jonathan W. Yewdell, NIAID, National Institutes of Health, USA
Induction of TCD8+ Responses by Viruses

Eli Gilboa, University of Miami, Miller School of Medicine, USA
Therapeutic Vaccination with mRNA Transfected Dendritic Cells for Cancer and Infectious Diseases

Immediate Early Steps in Viral Entry and Uncoating

Ballroom C
* John P. Moore, Weill Medical College of Cornell University, USA
Effect of a Small Molecule CCR5 Inhibitor on Virus Infection in the Rhesus Macaque

John A. T. Young, F.Hoffmann-La Roche Ltd, Switzerland
Cellular Factor Requirement in HIV-1 Uncoating Revealed by a Cell-Free System

Christopher Aiken, Vanderbilt University School of Medicine, USA
Capsid Disassembly and HIV-1 Infection

Thomas J. Hope, Northwestern University, USA
HIV Entry and Early Events (Cytoplasmic Trafficking)

Vineet N. KewalRamani, NCI, National Institutes of Health, USA
Cell and Molecular Requirements for DC-SIGN-Mediated HIV Transmission

Social Hour

Ballroom A, Grand Foyer
Poster Session 2

Ballroom A, Grand Foyer



Lower Level
Innate Intracellular Antiviral Responses (Joint)

Ballroom B, C
Michael H. Malim, King's College London, UK
Vif, cytidine deamination and HIV replication

Warner Craig Greene, Gladstone Institute of Virology and Immunology, USA
HIV Vif versus the Antiviral APOBEC3G Enzyme: New Insights into the Mechanism of Vif Action

Didier Trono, Ecole Polytechnique Fédérale de Lausanne, Switzerland
Innate Intracellular defenses Against Retroelements

* Stephen P. Goff, Columbia University, USA
Cellular Blocks to HIV and MuLV Infection

Jonathan P. Stoye, Francis Crick Institute, UK
Fv1 and Related Retrovirus Restriction Genes

Jaisri R. Lingappa, University of Washington, USA
HP68/RNase L Inhibitor: A Host Factor Critical for Virion Assembly

Coffee Break

Grand Foyer
Poster Setup

Ballroom A, Grand Foyer
Poster Viewing

Ballroom A, Grand Foyer
Workshop 3: Mechanisms of Antibody-Mediated Neutralization and Escape

Ballroom B, C
* John R. Mascola, NIAID, National Institutes of Health, USA

Ruth A. McCaffrey, Seattle Biomedical Research Institute, USA
The Immunologically ‘Silent’ Face of gp120 Protects HIV-1 SF162 from Neutralization by Anti-gp120 and Anti-gp41 Antibodies

Carol D. Weiss, US Food and Drug Administration, USA
Escaping Fusion Inhibition: Elusive Tactics of the HIV Envelope Glycoprotein

Robert G. Whalen, Altravax, Inc., USA
Creating Improved Viral Immunogens by Directed Molecular Evolution

Kelly A. Stefano Cole, University of Pittsburgh School of Medicine, USA
Characterization of Antibody Binding Properties Associated with Neutralization of SIV

Ralph A. Pantophlet, Simon Fraser University, Canada
Immunofocusing: Re-Engineering Monomeric gp120 to Promote the Induction of HIV-Neutralizing Antibodies

Cheryl A. Pikora, New England Regional Primate Research Center, USA
Persistence of Neutralization Resistance Despite Removal of gp120, Core, N-linked Glycosylation Sites in SIV239

Miroslaw K. Gorny, New York University School of Medicine, USA
Identification of a New Neutralizing Epitope in gp120

Workshop 3: Neuro AIDS and Latency
Attendance Limited to 125

Garibaldi A/B
* Janice E. Clements, Johns Hopkins University, USA

Paul R. Gorry, RMIT University, Australia
Longitudinal Analysis of nef/LTR-Deleted HIV-1 in Blood and CSF of a Long-Term Survivor who Developed HIV-Associated Dementia

Evelyne E. Schaeffer, Centre de Neurochimie, France
Role of the Envelope in HIV-1 Induced Direct Neuronal Cell Damage

Paul R. Clapham, University of Massachusetts Medical School, USA
Biological Analysis of HIV-1 R5 Envelopes Amplified by PCR from Brain and Lymph Node Tissue of AIDS Patients with Neuropathology

Justyna M. Dudaronek, Johns Hopkins School of Medicine, USA
Regulation of Viral Gene Expression in the CNS by Innate Immune Responses during Acute SIV Infection

Michael R. Nonnemacher, Drexel University College of Medicine, USA
An Enhanced Preference for a High Affinity Interaction between HIV-1 Vpr and Sequences within C/EBP Site I Correlates with HIV-1 Associated Dementia

Yefei Han, Johns Hopkins School of Medicine, USA
Latent HIV-1 Genomes Reside in Actively Transcribed Genes in Resting CD4+ T Cells in vivo

Samuel Ambler Williams, Gladstone Institute, USA
NF-kappaB/Rel Transcription Factors and the Regulation of HIV Postintegration Latency

Leor S. Weinberger, University of California, San Francisco, USA
Stochastic Switching in HIV-1 Tat Transactivation as a Possible Mechanism Leading to HIV-1 Proviral Latency

Coffee & Snacks Available

Grand Foyer
HIV Genetic Variation (Joint)

Ballroom B, C
Francine McCutchan, PATH, USA
Molecular Epidemiology of the Global HIV-1 Pandemic

* Bette Tina Marie Korber, Los Alamos National Laboratory, USA
Neutralization Antibody Signature Patterns in HIV Sequences

Todd M. Allen, Ragon Institute of MGH, MIT and Harvard, USA
Short Talk: Stereotypic Escape from CD8T Cell Responses as a Major Driving Force of HIV-1 Sequence Evolution

Dean H. Hamer, National Institutes of Health, USA
Short Talk: HIV-Specific CD4 T Cells are a Hot Spot for Viral Evolution

Social Hour

Ballroom A, Grand Foyer
Poster Session 3

Ballroom A, Grand Foyer



Lower Level
Novel Approaches to HIV Vaccination

Ballroom B
Jeffrey D. Lifson, Leidos Biomedical Research, Inc., USA
Whole Inactivated AIDS Virus Virions with Functional Envelope Glycoproteins

Richard W. Compans, Emory University, Rollins Research Center, USA
Virus-like Particles as HIV Immunogens

* Norman L. Letvin, Beth Israel Deaconess Medical Center, USA
A Multi-Clade Envelope-Based Vaccine Strategy for HIV

Stephen A. Udem, Wyeth Pharmaceuticals, USA
VSV as an HIV Vaccine Vector

Hildegund C.J. Ertl, Wistar Institute, USA
Simian-Derived E1-Deleted Adenovirus Vectors for HIV Vaccination

Dan H. Barouch, Beth Israel Deaconess Medical Center, USA
Short Talk: Low Seroprevalence of Adenovirus Serotype 35 and Immunogenicity of rAd35-Gag Vaccine in Mice with Pre-Existing Anti-Ad5 Immunity

Adam C. Soloff, University of Pittsburgh, USA
Short Talk: Dual Adenoviral-Based Vaccination Using Serotypes 5 and 35 Induces Broad T Cell Responses to SIV which are Recalled with Heterologous Challenge

Nef Function

Ballroom C
John C. Guatelli, University of California, San Diego, USA
Nef, Intracellular Protein Trafficking, and Viral Infectivity

* Kathleen L. Collins, University of Michigan Medical Center, USA
Nef-Mediated MHC-1 Downmodulation in T Cells

Kalle Saksela, University of Helsinki, Finland
Cellular Activation by HIV-1 Accessory Proteins

Andreas Stephan Baur, , Germany
Nef Signaling in T Cells and HIV Replication: New Insights into the Molecular Mechanism

Olivier Schwartz, Institut Pasteur, France
Role of HIV-1 Nef during Viral Replication in Primary Cells

Coffee Break

Grand Foyer
Poster Setup

Ballroom A, Grand Foyer
Poster Viewing

Ballroom A, Grand Foyer
Workshop 4: HIV-Immune Evasion

Ballroom B
Marcus Altfeld, Heinrich-Pette-Institute, Germany
Selection, Transmission, and Reversion of an Antigen Processing CTL Escape Mutation in HIV-1

Annika C. Karlsson, Karolinska Institutet, Sweden
Cellular Immune Responses and Viral Escape in HLA-A2-Positive Patients Following Primary HIV-1 Infection

Sylvie Le Gall, Massachusetts General Hospital, Harvard Medical School, USA
An HLA B57-Specific Mutation Outside an Immunodominant Epitope Alters Antigen Processing and Leads to CTL Escape

Todd M. Allen, Ragon Institute of MGH, MIT and Harvard, USA
CD8 T Cell Responses and Viral Escape in HIV-Infected Monozygotic Twins Infected with the Same Virus

Astrid K.N. Iversen, Weatherall Institute of Molecular Medicine, UK
Functional and Structural Basis for HIV Escape from T Cell Recognition

Wendy M. Blay, Seattle Biomedical Research Institute, USA
Potential N-Linked Glycosylation Sites Undergo Predictable Patterns of Variation within Constrained Regions of HIV-1 Envelope

Workshop 4: HIV Entry, Early Events

Ballroom C
* Didier Trono, Ecole Polytechnique Fédérale de Lausanne, Switzerland

Sophie Holuigue, Windeyer Institute of Medical Sciences, University College London, UK
Antibodies Capable of Inactivating HIV-1 Arise Coincidentally with the Initial Decline in Viral Load during acute Infection

Severine Bär, Deutsches Krebsforschungszentrum, germany
Dissecting Steps of gp41-Mediated Membrane Fusion by Quantitative Assays Based on Flow Cytometry: Involvement of the Loop Region in Post Lipid Mixing Events

Ariberto Fassati, University College London, UK
Importin 7 Mediates Nuclear Import of HIV-1 Intracellular Reverse Transcription Complexes

Eric Poeschla, University of Colorado School of Medicine, USA
LEDGF/p75 Determines Cellular Trafficking of Diverse Lentiviral but not Oncoretroviral Integrase Proteins and is a Component of Functional HIV-1 Pre-Integration Complexes

Robert J. Gorelick, National Cancer Institute at Frederick, USA
Involvement of the HIV-1 Nucleocapsid Protein in the Synthesis and Integration of the Viral DNA during Infection

Malini Mansharamani, Johns Hopkins School of Medicine, USA
Barrier-to-Autointegration Factor (BAF) Binds HIV-1 Gag and MA Proteins

Kelly M. Champagne, Thomas Jefferson University, USA
The Structure and Folding of a Designed HIV-1 Entry Inhibitor

Hugues J.P. Ryser, Boston University School of Medicine, USA
PDI-Mediated Reduction of Disulfide Bonds in Envelope Glycoprotein gp120 is Required for HIV-1 Entry

Alexa Raney, University of Texas Southwestern Medical Center, USA
In vitro Reconstitution of an Active Pak2/Nef Complex

Coffee & Snacks Available

Grand Foyer
Therapeutic Vaccination of HIV-Infected Individuals

Ballroom B
Brigitte Autran, Hôpital Pitié-Salpétrière, UPMC, France
Therapeutic Immunization against HIV

Richard A. Koup, NIAID, National Institutes of Health, USA
Therapeutic Vaccines: Hypothesis Testing in vivo

* Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, USA
Stimulating Cellular Immunity with Dendritic Cell Based Vaccines

Bruce D. Walker, Ragon Institute of MGH, MIT and Harvard, USA
Immunology and virology of controlled HIV infection


Ballroom C
* Dana H. Gabuzda, Dana Farber Cancer Institute, USA
Mechanisms of Neuropathogenesis

Francisco González-Scarano, University of Texas Health Science Center at San Antonio, USA
Determinants of Microglial/Macrophage Tropism and Replication

Karl-Heinz Krause, University of Geneva Faculty of Medicine, Switzerland
HIV, CCR5, and Neurodegeneration

Andrew A. Lackner, Tulane National Primate Research Center, USA
Early Events in the Neuropathogenesis of AIDS

Social Hour

Ballroom A, Grand Foyer
Poster Session 4

Ballroom A, Grand Foyer



Lower Level
Lessons for HIV Vaccine Development from other Vaccines

Ballroom B
William R. Jacobs, Jr., HHMI/Albert Einstein College of Medicine, USA
Novel Strategies for Vaccine Protection Against M. tuberculosis

* Kanta Subbarao, WHO Collaborating Centre for Reference and Research on Influenza, Australia
Preventing Pandemics and Newly Emerging Respiratory Viral Threats through Vaccine Development

Kathrin U. Jansen, Pfizer, USA
Status of Prophylatic Vaccines Against Cervical Cancer

Drew M. Pardoll, Johns Hopkins University School of Medicine, USA
Novel Vaccine Strategies for the Treatment of Cancer

Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
Immunotherapy of Cancer: Lessons Learned from Melanoma

HIV-1 in the Nucleus

Ballroom C
Frederic D. Bushman, University of Pennsylvania, USA
DNA Integration by Retroviruses in the Human Genome

* Michael Emerman, Fred Hutchinson Cancer Research Center, USA
HIV Infection of Non-Dividing Cells

Katherine A. Jones, The Salk Institute, USA
The c-Ski-Interacting Protein (SKIP) Facilitates Transcription Elongation by HIV-1 Tat

Barbara K. Felber, NCI, National Institutes of Health, USA
HIV Posttranscriptional Regulation and Viral Latency

Eric M. Verdin, Buck Institute for Research on Aging, USA
Molecular Mechanisms of HIV Latency

Coffee Break

Grand Foyer
Coffee & Snacks Available

Grand Foyer
Mechanisms of HIV Immune Evasion

Ballroom B
* George M. Shaw, University of Pennsylvania, USA
Immune Control and Escape by HIV-1: Neutralizing Antibodies

Persephone Borrow, University of Oxford, UK
Escape of HIV-1 from the Primary CTL Response

David I. Watkins, University of Miami, USA
SIV Escape from CTL

Philip J. Goulder, University of Oxford, UK
HIV Evolution: CTL Escape Mutation and Reversion following Transmission

HIV-1 and Protein Trafficking in the Cytoplasm

Ballroom C
* Beatrice H. Hahn, University of Pennsylvania, USA

Mark Marsh, University College London, UK
HIV Assembly in the Endocytic Pathway

Markus Thali, University of Vermont, USA
HIV-1 Egress is Gated Through Late Endosomal Membranes

Ganjam V. Kalpana, Albert Einstein College of Medicine, USA
A Novel INI1/hSNF5 Associated HDAC1 Complex is Specifically Incorporated into HIV-1 Virions and is Required for Viral Early Events

Benjamin K. Chen, Mount Sinai School of Medicine, USA
Chimeric Virus Models to Understand HIV-1 Assembly

Paul D. Bieniasz, Rockefeller University, USA
GAG Localization and Interaction with Host Factors during Retrovirus Assembly and Budding

Social Hour

Ballroom A

Ballroom A



*Session Chair †Invited, not yet responded.

We gratefully acknowledge the generous grant for this conference provided by:

National Institutes of Health

Grant No. 1R13AI58748-01

We gratefully acknowledge additional support for this conference from:

Beckman Coulter Foundation, Inc. Bill & Melinda Gates Foundation
Office of AIDS Research, NIH Wyeth Vaccines Research

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Corporate Relations, Email:,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email:,
Phone:+1 970-262-1179